Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18326377 | 0.81 | SCN9A (0.47) | SCN9AHTR2AHTR2CKMT2APKM | |
| SCHEMBL16896733 | 0.81 | BRD4 (0.53) | SCN9A | |
| SCHEMBL18326372 | 0.77 | SCN9A (0.47) | SCN9AHTR2AHTR2CKMT2APKM | |
| SCHEMBL16905984 | 0.74 | BRD4 (0.54) | SCN9AHTR2AHTR2CKMT2APKM | |
| SCHEMBL20357596 | 0.70 | BRD4 (0.46) | SCN9AKMT2APKMMEN1ALDH1A1 | |
| SCHEMBL18359585 | 0.69 | HTR2A (0.45) | HTR2AHTR2CKMT2APKMMEN1 | |
| SCHEMBL16896825 | 0.68 | HTR2A (0.44) | HTR2AHTR2CKMT2APKMMEN1 | |
| SCHEMBL29732326 | 0.67 | GABRA5 (0.45) | HTR2AHTR2CKMT2AMEN1ALDH1A1 | |
| SCHEMBL18326378 | 0.67 | GABRA5 (0.45) | HTR2AHTR2CKMT2AMEN1ALDH1A1 | |
| SCHEMBL16905985 | 0.67 | ALDH1A1 (0.48) | SCN9AHTR2AHTR2CALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2020-03-17 | — | — | US | disclosed |
| EP-3092227-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-07-11 | — | — | EP | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | SCN9A 1742/4885HTR2A 2532/4885HTR2C 1545/4885 |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | SCN9A 1742/4885HTR2A 2532/4885HTR2C 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.